Treatment Options and Protecting Your Kidneys
At a Glance
Arterionephrosclerosis is managed mainly by individualized blood pressure control, often with kidney-protective medicines such as ACE inhibitors, ARBs, or SGLT2 inhibitors. Lower sodium, avoid NSAIDs, and regular blood tests help protect kidney function.
The single most important treatment for arterionephrosclerosis is controlling your blood pressure. High pressure acts like a physical force that scars the kidney’s delicate filters over time [1].
Current international guidelines (KDIGO) recommend a target systolic blood pressure (the top number) of less than 120 mmHg for most adults with chronic kidney disease [2][3]. However, this target is based on “standardized” readings—meaning measurements taken after you have rested quietly for five minutes, using a proper cuff size and position [3][2]. This target applies only to standardized office measurements, not home or routine clinic readings. You should not adjust medications to force a home reading below 120. Your doctor will individualize this goal based on your age, other health conditions, and how well you tolerate the medication [4].
First-Line Protection: ACEi and ARBs
Two classes of medication are considered the “gold standard” for protecting kidneys damaged by high blood pressure: ACE inhibitors (like lisinopril) and Angiotensin Receptor Blockers (ARBs) (like losartan) [5][6]. These drugs are considered the ‘gold standard’ primarily for patients with elevated albuminuria. They require blood tests 1-4 weeks after starting to check creatinine and potassium, and are contraindicated in pregnancy. They can also cause side effects like a dry cough or angioedema.
These drugs do more than just lower blood pressure in your arm; they specifically lower the pressure inside the kidney’s filters (glomeruli) [6]. This “mechanical” relief helps slow down the progression of scarring and reduces the amount of protein leaking into your urine (albuminuria) [5].
A Critical Warning: You should never take an ACE inhibitor and an ARB at the same time. This “dual blockade” does not provide extra benefit but significantly increases your risk of acute kidney injury and dangerously high potassium levels (hyperkalemia) [7][5].
The New Standard: SGLT2 Inhibitors
In recent years, a class of drugs called SGLT2 inhibitors (like dapagliflozin or empagliflozin) has emerged as a powerful “add-on” therapy [8]. Originally used for diabetes, they are now recommended for many patients with kidney disease even if they do not have diabetes [8][9]. Eligibility depends on specific eGFR, albuminuria, and heart failure status. The 37% risk reduction was observed in clinical trials and varies by individual. SGLT2 inhibitors carry risks of genital yeast infections, volume depletion, and rarely, diabetic ketoacidosis, and may require sick-day holds. These medications can reduce the risk of kidney disease progression by approximately 37% [9].
Managing Fluid and Resistance
If blood pressure remains high despite first-line therapy, your doctor may add other medications:
- Diuretics: These help your body get rid of excess salt and water. A long-acting diuretic called chlorthalidone can be effective even in advanced stages of kidney disease [10][11].
- Calcium Channel Blockers: Medications like amlodipine are often added as a third step to help relax blood vessels [10].
- Spironolactone: This is used for “resistant” hypertension. While effective, it carries a higher risk of hyperkalemia (high potassium) in patients with kidney disease, so it requires very close blood test monitoring [12][13].
Daily Habits That Protect Your Kidneys
Medication works best when supported by your daily choices. Two key areas are:
- Sodium Restriction: Consuming less than 2 grams of sodium per day (about one teaspoon of salt) is a cornerstone of treatment [14]. (Note: 2 grams of sodium equals about 5 grams, or one teaspoon, of table salt, which is mostly hidden in packaged foods. Avoid potassium-containing salt substitutes if on ACEi, ARB, or spironolactone). Reducing salt helps your blood pressure medications work more effectively and reduces fluid strain on your heart and kidneys [14][15].
- Avoiding NSAIDs: Common over-the-counter pain relievers known as NSAIDs (like ibuprofen and naproxen) can reduce blood flow to the kidneys and interfere with your blood pressure medications [16]. Acetaminophen must be cleared by a pharmacist or clinician due to liver safety limits. Patients with kidney disease are generally advised to avoid these and use alternatives like acetaminophen after consulting their doctor.
What to Expect When Starting Treatment
When you start a kidney-protective medication, it is normal to see a small, early dip in your kidney function (eGFR) on your blood tests [6][17]. This is often a sign that the medication is successfully lowering the internal pressure in your kidneys. While a modest dip is a functional change, a drop greater than 30% or drops accompanied by dehydration and low blood pressure require immediate clinical evaluation. Your doctor will monitor your blood work closely to ensure the change stays within a safe range [17].
Common questions in this guide
What is the main treatment for arterionephrosclerosis?
Can I take an ACE inhibitor and an ARB together?
Could an SGLT2 inhibitor help if I do not have diabetes?
What blood tests are needed after starting kidney-protective medicine?
How much salt should I eat with arterionephrosclerosis?
Which pain relievers are unsafe for my kidneys?
Appointments are short. Make every minute count.
Specialist visits move fast. Let us help you prep so your time goes to what matters.
Blood pressure goals
What blood pressure goal would be right for me, and how would you individualize it?
Pain relievers
Which pain relievers should I avoid, and what alternatives would you suggest?
Daily habits
Would reducing salt be a helpful step for me to discuss with you?
Get notified when new evidence is published on arterionephrosclerosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (17)
- 1
Hypertensive Nephrosclerosis: Pathological Changes and Overlap with Diabetic Nephropathy.
Qasim H, Ktaifan M, Awawdeh A, et al.
Cureus 2025; (17(9)):e92949 doi:10.7759/cureus.92949.
PMID: 41141162 - 2
Commentary on the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in CKD.
Mann JFE, Chang TI, Cushman WC, et al.
Current cardiology reports 2021; (23(9)):132 doi:10.1007/s11886-021-01559-3.
PMID: 34398316 - 3
Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease.
Cheung AK, Chang TI, Cushman WC, et al.
Kidney international 2021; (99(3)):559-569 doi:10.1016/j.kint.2020.10.026.
PMID: 33637203 - 4
Controversies in Hypertension II: The Optimal Target Blood Pressure.
Filippone EJ, Foy AJ, Naccarelli GV
The American journal of medicine 2022; (135(10)):1168-1177.e3 doi:10.1016/j.amjmed.2022.05.009.
PMID: 35636475 - 5
[Classical nephroprotection: Renin angiotensin aldosterone system inhibitors].
Egocheaga MI, Drak Y, Otero V
Semergen 2023; (49 Suppl 1()):102018 doi:10.1016/j.semerg.2023.102018.
PMID: 37355297 - 6
Submaximal Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Dosing Among Persons With Proteinuria.
Chu CD, Powe NR, Estrella MM, et al.
Mayo Clinic proceedings 2022; (97(11)):2099-2106 doi:10.1016/j.mayocp.2022.07.010.
PMID: 36210196 - 7
The association between dual RAAS inhibition and risk of acute kidney injury and hyperkalemia in patients with diabetic kidney disease: a systematic review and meta-analysis.
Whitlock R, Leon SJ, Manacsa H, et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2023; (38(11)):2503-2516 doi:10.1093/ndt/gfad101.
PMID: 37309038 - 8
[Retard chronic kidney disease progression].
Schuller M, Saritas T
Deutsche medizinische Wochenschrift (1946) 2024; (149(6)):320-325 doi:10.1055/a-1941-7057.
PMID: 38412989 - 9
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
,
Lancet (London, England) 2022; (400(10365)):1788-1801 doi:10.1016/S0140-6736(22)02074-8.
PMID: 36351458 - 10
Diuretics in patients with chronic kidney disease.
Agarwal R, Verma A, Georgianos PI
Nature reviews. Nephrology 2025; (21(4)):264-278 doi:10.1038/s41581-024-00918-x.
PMID: 39775051 - 11
Should we CLICK on chlorthalidone for treatment-resistant hypertension in chronic kidney disease?
Agarwal R
Clinical kidney journal 2023; (16(5)):793-796 doi:10.1093/ckj/sfac272.
PMID: 37151421 - 12
Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis.
Currie G, Taylor AH, Fujita T, et al.
BMC nephrology 2016; (17(1)):127 doi:10.1186/s12882-016-0337-0.
PMID: 27609359 - 13
Resistant Hypertension in Chronic Kidney Disease (CKD): Prevalence, Treatment Particularities, and Research Agenda.
Georgianos PI, Agarwal R
Current hypertension reports 2020; (22(10)):84 doi:10.1007/s11906-020-01081-x.
PMID: 32880742 - 14
Hypertension in chronic kidney disease-treatment standard 2023.
Georgianos PI, Agarwal R
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2023; (38(12)):2694-2703 doi:10.1093/ndt/gfad118.
PMID: 37355779 - 15
Salt-sensitive hypertension in chronic kidney disease: distal tubular mechanisms.
Bovée DM, Cuevas CA, Zietse R, et al.
American journal of physiology. Renal physiology 2020; (319(5)):F729-F745 doi:10.1152/ajprenal.00407.2020.
PMID: 32985236 - 16
Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease: Clinical Evidence, Pharmacology, and Drug-Drug Interactions for Personalized Management of Hyperkalemia.
Hirai T, Katayama K
International journal of molecular sciences 2026; (27(10)) doi:10.3390/ijms27104272.
PMID: 42196253 - 17
Causal Effects of Renin-Angiotensin-Aldosterone System Inhibition on Renal Function in Patients With Chronic Kidney Disease: A Quasi-Experimental Study.
Oh TR, Park J, Choi HS, et al.
Clinical and translational science 2026; (19(4)):e70533 doi:10.1111/cts.70533.
PMID: 41876398
This page explains treatment approaches for arterionephrosclerosis for educational purposes and is not medical advice. Your clinician should set your blood pressure target and review your medicines, symptoms, and laboratory results.